基因疗法：癌症免疫刺激疗法的发展 - Suppr

Suppr

超能文献

Gene therapy: development of immunostimulatory treatments for cancer.

作者信息

Gilligan M G, Knox P G, Searle P F

机构信息

University of Birmingham CRC Institute for Cancer Studies, Medical School, Edgbaston, Birmingham B15 2TA, U.K.

出版信息

Biotechnol Genet Eng Rev. 2000;17:497-529. doi: 10.1080/02648725.2000.10648003.

DOI:10.1080/02648725.2000.10648003

PMID:11255679

Abstract

摘要

相似文献

Gene therapy: development of immunostimulatory treatments for cancer.

Biotechnol Genet Eng Rev. 2000;17:497-529. doi: 10.1080/02648725.2000.10648003.

Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.

Melanoma Res. 2011 Oct;21(5):438-45. doi: 10.1097/CMR.0b013e32834640c0.

Viral vectors for gene transfer into antigen presenting cells.

Curr Opin Mol Ther. 1999 Oct;1(5):558-64.

When transgenes shape immunity: cancer immune-gene therapy.

J Gene Med. 2012 Jun;14(6):384-5. doi: 10.1002/jgm.2645.

Dendritic cells: emerging roles in tumor immunotherapy.

Clin J Oncol Nurs. 2006 Oct;10(5):629-40. doi: 10.1188/06.CJON.629-640.

Immunostimulatory DNA sequences and cancer therapy.

Springer Semin Immunopathol. 2000;22(1-2):107-16. doi: 10.1007/s002810000022.

Dendritic cells and cytokines in immune rejection of cancer.

Cytokine Growth Factor Rev. 2008 Feb;19(1):93-107. doi: 10.1016/j.cytogfr.2007.10.003. Epub 2007 Dec 3.

Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.

Expert Opin Biol Ther. 2004 Nov;4(11):1735-47. doi: 10.1517/14712598.4.11.1735.

Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.

Cell Biol Toxicol. 2001;17(2):67-75. doi: 10.1023/a:1010944003649.

Cancer vaccines: dream, reality, or nightmare?

Clin Exp Med. 2002 Nov;2(3):109-18. doi: 10.1007/s102380200015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Gene therapy: development of immunostimulatory treatments for cancer.

Biotechnol Genet Eng Rev. 2000;17:497-529. doi: 10.1080/02648725.2000.10648003.

Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.

Melanoma Res. 2011 Oct;21(5):438-45. doi: 10.1097/CMR.0b013e32834640c0.

Viral vectors for gene transfer into antigen presenting cells.

Curr Opin Mol Ther. 1999 Oct;1(5):558-64.

When transgenes shape immunity: cancer immune-gene therapy.

J Gene Med. 2012 Jun;14(6):384-5. doi: 10.1002/jgm.2645.

Dendritic cells: emerging roles in tumor immunotherapy.

Clin J Oncol Nurs. 2006 Oct;10(5):629-40. doi: 10.1188/06.CJON.629-640.

Immunostimulatory DNA sequences and cancer therapy.

Springer Semin Immunopathol. 2000;22(1-2):107-16. doi: 10.1007/s002810000022.

Dendritic cells and cytokines in immune rejection of cancer.

Cytokine Growth Factor Rev. 2008 Feb;19(1):93-107. doi: 10.1016/j.cytogfr.2007.10.003. Epub 2007 Dec 3.

Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.

Expert Opin Biol Ther. 2004 Nov;4(11):1735-47. doi: 10.1517/14712598.4.11.1735.

Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.

Cell Biol Toxicol. 2001;17(2):67-75. doi: 10.1023/a:1010944003649.

Cancer vaccines: dream, reality, or nightmare?

Clin Exp Med. 2002 Nov;2(3):109-18. doi: 10.1007/s102380200015.